Imatinib use in the management of a patient with Doege-Potter syndrome.

José Luis Paz-Ibarra Jose Lu-Antara Brenda-Erendida Uscamayta Jhancy Martinez-Auris Miriam Valencia-Rivera Sofia Mabel Sáenz-Bustamante Marialejandra Delgado-Rojas Julia Salcedo-Vasquez Marcio José Concepción-Zavaleta

Published in: Endocrinology, diabetes & metabolism case reports (2023)

Doege-Potter syndrome (DPS) is a rare cause of tumoral hypoglycemia of non-pancreatic origin. Some malignant or benignant neoplasms have ectopic secretion of insulin-like growth factor-2. Total surgical removal is the principal treatment in patients with DPS. Tyrosine kinase inhibitors management in DPS may contribute to improved tumor control in patients with unresectable tumors and severe hypoglycemia.

Keyphrases

case report
type diabetes
chronic myeloid leukemia
squamous cell carcinoma
early onset
metabolic syndrome
radiation therapy
combination therapy
insulin resistance
replacement therapy
smoking cessation